CIN2 and CIN3 are grades of abnormal cell changes in the lining of the cervix, almost always caused by a persistent infection with high-risk strains of human papillomavirus (HPV). They are not cancer, but they are considered precancerous because, without monitoring or treatment, they carry a real risk of eventually becoming cervical cancer. The key difference between them is how much of the cervical lining is affected by abnormal cells.
How CIN2 and CIN3 Are Defined
The surface of your cervix is lined by a thin layer of tissue called the epithelium. When a pathologist examines a biopsy under a microscope, they look at how much of that layer has been replaced by abnormal cells. In CIN2, abnormal cells extend through roughly one-third to two-thirds of the epithelium’s thickness. In CIN3, abnormal cells take up more than two-thirds. For comparison, CIN1, the mildest grade, involves only the bottom third and usually resolves on its own.
In practice, the line between CIN2 and CIN3 can be blurry even for experienced pathologists. That’s why many labs now use a two-tier system instead of three tiers. Under this newer classification, CIN3 and certain CIN2 cases are grouped together as “high-grade squamous intraepithelial lesions” (HSIL). To sort CIN2 into the right category, pathologists often use a special stain called p16. If the CIN2 biopsy stains strongly positive for p16, it behaves more like CIN3 and is classified as high-grade. If p16 is negative, the cells behave more like CIN1, and the case is reclassified as low-grade. This distinction matters because it directly shapes whether you’ll be offered treatment right away or monitored over time.
What Causes These Changes
Nearly all CIN2 and CIN3 cases are driven by persistent infection with high-risk HPV types. HPV 16 is by far the most common strain found in these lesions, followed by HPV 33, 31, 52, and 18. Most HPV infections clear on their own within a year or two. CIN2 and CIN3 develop when a high-risk strain persists for years, allowing the virus to progressively disrupt normal cell growth in the cervical lining.
Risk of Progression to Cancer
CIN2 and CIN3 sit at very different points on the risk spectrum. CIN2 has a strong tendency to resolve without treatment, especially in younger women. In women under 25, studies have found that roughly 88% of CIN2 cases regress partially or completely during a period of active monitoring. Broader research across age groups puts regression rates between 39% and 71%, with progression to a higher grade occurring in about 8% to 17% of cases.
CIN3 is more concerning. Left untreated, an estimated 12% to 40% of CIN3 cases will eventually progress to invasive cervical cancer. That progression is slow, typically unfolding over many years. The average interval between CIN3 and invasive cancer is estimated at around 13 years, with the likelihood of progression roughly 1% per year. That long timeline is why screening catches most cases well before they become dangerous, but it’s also why CIN3 is treated rather than simply watched.
How CIN2 and CIN3 Are Managed
CIN3 is treated with an excisional procedure in nearly all cases. CIN2 management depends heavily on your age and whether you plan to have children in the future.
Observation for CIN2
For women ages 21 to 24, observation is the preferred approach because of the high spontaneous regression rate in this age group. This means returning for colposcopy and a Pap test every six months for up to two years. If the abnormality persists at 24 months, treatment is recommended. Women 25 and older who still want to become pregnant can also be offered observation on the same schedule, though excision is generally preferred once childbearing is complete. Your preferences matter here, and this is a decision you and your provider make together based on your age, your plans, and your biopsy results.
Excisional Treatment
The two most common procedures for removing CIN2 or CIN3 are LEEP (loop electrosurgical excision procedure) and cold knife conization. In a LEEP, a thin heated wire loop shaves away the abnormal area of the cervix. It’s typically done in a clinic under local anesthesia and takes about 10 to 20 minutes. Cold knife conization is a surgical procedure that removes a cone-shaped wedge of cervical tissue, usually under general anesthesia, and it cuts deeper into the cervix.
A large meta-analysis comparing the two found no significant difference in recurrence rates, residual disease, or major complications. LEEP and cold knife conization are considered equally effective. One difference: cold knife conization removes a deeper cone of tissue, which gives it a slightly lower rate of positive margins (13% vs. 22% for LEEP). A positive margin means abnormal cells were found at the edge of the removed tissue, which may require closer follow-up but doesn’t necessarily mean abnormal cells were left behind. For women over 45, cold knife conization may be preferred when achieving clear margins is a priority.
Follow-Up After Treatment
Treatment for CIN2 or CIN3 is highly effective, but follow-up is important because there is a small ongoing risk of recurrence. Current guidelines recommend HPV testing or co-testing (HPV test plus Pap) every three years after treatment for at least 25 years. If HPV-based testing isn’t available, annual Pap tests are an acceptable alternative. This extended surveillance window reflects the fact that the HPV virus can remain dormant and reactivate, so even a successful procedure doesn’t eliminate the need for regular screening.
Effects on Future Pregnancies
If you’re planning to become pregnant after treatment, the most important thing to know is that excisional procedures are linked to a higher risk of preterm delivery. A large register-based study found that women who had undergone excisional treatment had about 1.6 times the odds of preterm delivery compared to women with untreated CIN. The risk of water breaking early (preterm prelabor rupture of membranes) was nearly 2.7 times higher.
These risks increase with the depth of tissue removed. Even small excisions of 10 millimeters or less carried a measurably elevated risk, and above 10 mm, the risk of preterm delivery increased by about 15% for each additional millimeter of depth. There is no “safe” cone length that eliminates the risk entirely, which is one reason younger women with CIN2 are often offered observation first. If you do need treatment and want children later, discuss the depth of excision with your provider, as keeping the cone as shallow as possible while still removing the abnormal tissue is an important consideration.